The Quantellect read.As of Nov 19, 2026, 20 active firms cover BridgeBio Pharma Inc: 18 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $87.00 to $156.00, a moderate spread. The average target of $110.43 sits 42% above the current $78.02. The rating mix has stayed broadly stable, with Buy-side ratings easing from 20 to 18 over recent months. On the fundamentals, the Street sees revenue growth near 90% this year and 70% next, consensus EPS building from about $-0.37 next quarter toward $-0.27 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS20 active firms
Buy
Strong Buy00%
Buy1890%
Neutral210%
Sell00%
Strong Sell00%
Based on 20 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$110.43
+41.5% upside
Average target across 14 active firms as of Nov 19, 2026 vs $78.02 current
Highest Target$156.00
Average Target$110.43
Lowest Target$87.00
Detailed analyst forecasts for BBIO
Showing 1–15 of 15 named analysts shown · 20 active firms in the rating projection
As of Nov 19, 2026, 18 of 20 active firms rate BBIO a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
BBIO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.37
Range $-0.62 – $-0.15 · 4 analysts · -56% YoY
Next period, 4 analysts expect BridgeBio Pharma Inc to earn $-0.37 a share (range $-0.62 – $-0.15), versus $-0.84 a year earlier. Full-year consensus is $-2.45, growing to $-0.27 the year after.
REVENUE · NEXT QUARTER
$338.1M
Range $323.0M – $350.8M · 4 analysts · +108% YoY
Revenue is expected to reach $338.1M (range $323.0M – $350.8M), +108.0% year-over-year. Full-year consensus is $1.1B, rising to $1.7B next year.
Top analysts covering BridgeBio Pharma Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BBIO.
#1
Luca Issi
RBC Capital · Rank #76
Buy
$100.00+28.2% to target
Overall win rate
49%
+ Follow
#2
Paul Choi
Goldman Sachs · Rank #110
Buy
$116.00+48.7% to target
Overall win rate
52%
+ Follow
#3
Anupam Rama
JP Morgan · Rank #171
Buy
$111.00+42.3% to target
Overall win rate
48%
+ Follow
#4
Greg Harrison
Scotiabank · Rank #223
Buy
$57.00-26.9% to target
Overall win rate
38%
+ Follow
#5
WI
Whitney Ijem
Canaccord Genuity · Rank #392
Buy
$106.00+35.9% to target
Overall win rate
35%
+ Follow
BBIO stock forecast FAQ
What is BBIO's average 12-month price target?+
The 14 active firms with a live target average $110.43 for BridgeBio Pharma Inc over the next 12 months, ranging from a $156.00 high to a $87.00 low, as of Nov 19, 2026.
Is BBIO stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 20 active firms as of Nov 19, 2026, 18 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for BBIO?+
The Street-high target is $156.00 (Barclays), and the Street-low is $87.00 (Morgan Stanley). The average of all 14 active-firm targets is $110.43.
How many active Wall Street firms cover BBIO?+
20 active firms have a recognized rating on BridgeBio Pharma Inc as of Nov 19, 2026, and 14 active firms carry a live 12-month price target.
Who is the most accurate analyst covering BBIO?+
Among analysts who currently cover BBIO, Luca Issi of RBC Capital has the strongest overall Quantellect track record (Rank #76). Their current call is Buy with a $100.00 target.
What is BridgeBio Pharma Inc's projected EPS for next quarter?+
The consensus estimate is $-0.37 per share (range $-0.62 – $-0.15) across 4 analysts. Full-year EPS is projected at $-2.45, rising to $-0.27 the following year.
How much revenue is BridgeBio Pharma Inc expected to report next quarter?+
Consensus revenue is $338.1M (range $323.0M – $350.8M). Full-year revenue is projected at $1.1B, growing to $1.7B next year.
Have analysts been upgrading or downgrading BBIO lately?+
As of Nov 19, 2026, 18 of 20 active firms rate BBIO a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BBIO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.